- 492 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
Antibody Drug Discovery
About this book
Monoclonal antibodies have become important treatments for cancer, inflammation and a wide range of other diseases, representing an increasing share of the most successful pharmaceutical markets. The technologies to discover these drugs have been developed by select centers of excellence in industry and academia, and are continually being fine tuned in the race to identify the best antibody-based drug candidates and accelerate their paths to patients. The objective of this volume is to provide a series of guides to those evaluating and preparing to enter particular areas within the field and to offer specialized perspectives to established researchers. The chapters set into context the significance of key developments and important considerations for selecting different approaches, such as antibody humanization, isotype selection, lead candidate selection criteria and protein production. All contributors to this work are experts in their fields, and many have played pivotal roles in the creation of these technologies.
Contents:
- Humanization of Antibodies (Olivier Léger and José W Saldanha)
- Selection and Screening of Antibody Phage Display Libraries (David R Buckler, Darren Schofield, Daniel J Sexton, David Lowe and Tristan J Vaughan)
- Affinity Maturation Approaches for Antibody Lead Optimization (David Lowe, Trevor Wilkinson and Tristan J Vaughan)
- Transgenic Mice Rearranging Human Antibodies (Sean Stevens)
- Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies (William R Strohl)
- Antibody Expression from Bacteria to Transgenic Animals (Paul Stephens and Berni M Sweeney)
- Current Trends in Antibody Purification and Lead Selection (Jie Chen and Andrew Nixon)
- Design and Application of Immunoconjugates for Cancer Therapy (Sherif El Sheikh, Hans-Georg Lerchen, Beate Müller-Tiemann and Jörg Willuda)
- Dual-Targeting Bispecific Antibodies as New Therapeutic Modalities for Cancer (Zhenping Zhu)
- Antibody Fragments and Alternate Protein Scaffolds (Lioudmila Tchistiakova, William J J Finlay, Stephane Olland, Helen Dooley and Davinder Gill)
Readership: Researchers in the field of antibody technology.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Cover Page
- Title Page
- Copyright Page
- Contents
- Contributors
- Foreword
- Preface
- Chapter 1: Humanization of Antibodies
- Chapter 2: Selection and Screening of Antibody Phage Display Libraries
- Chapter 3: Affinity Maturation Approaches for Antibody Lead Optimization
- Chapter 4: Transgenic Mice Rearranging Human Antibodies
- Chapter 5: Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies
- Chapter 6: Antibody Expression from Bacteria to Transgenic Animals
- Chapter 7: Current Trends in Antibody Purification and Lead Selection
- Chapter 8: Design and Application of Immunoconjugates for Cancer Therapy
- Chapter 9: Dual-Targeting Bispecific Antibodies as New Therapeutic Modalities for Cancer
- Chapter 10: Antibody Fragments and Alternate Protein Scaffolds
- Editor Biography
- Index